LX7101

Indications
Glaucoma

Stage of Development
Formal preclinical studies



Overview
Lexicon is developing LX7101 as a potential treatment for glaucoma that works by inhibiting a protein that regulates intraocular pressure (IOP) in the eye.  For additional information about the LX7101 program, please view our video presentation .
 

All forms of glaucoma damage the optic nerve, and may lead to blindness. 



Key Target
The target of LX7101 is a kinase that is responsible for regulating intraocular pressure.  IOP levels can become elevated due to increased resistance in the fluid outflow facility in the eye.  LX7101 is intended to lower IOP by enhancing the fluid outflow facility of the eye.  The goal of the LX7101 program is to develop a once-daily eye drop that lowers IOP by increasing the fluid outflow facility in the eye, a novel mechanism not currently addressed by approved products for glaucoma.

Aqueous humor, made by the ciliary body, continuously flows in and out of the eye.  The fluid leaves the eye at the open angle, flowing through the trabecular meshwork.  This mechanism, known as the fluid outflow facility, regulates IOP in the eye.  LX7101 reduces IOP by enhancing the fluid outflow facility of the eye.



Preclinical Data
In preclinical studies, a single topical dose of LX7101 significantly reduced IOP in a model of ocular hypertension.  Formal preclinical studies are in progress.